ASCO Annual Meeting: Melanoma | Conference

Lifileucel Continues to Show Durable Responses in Advanced Melanoma
June 06, 2021

With further follow-up, lifileucel (LN-144) continued to show durable responses in patients with heavily pretreated advanced or metastatic melanoma who have progressed on multiple therapies, including prior anti–PD-1/PD-L1 therapy

Lenvatinib-Pembrolizumab Combo Improves Outcomes in Certain Patients With Advanced Melanoma
June 06, 2021

In an updated analysis of the combination of lenvatinib and pembrolizumab for patients with advanced melanoma efficacy results continue to show a durable response.

Nivolumab Monotherapy, With Ipilimumab Continuously Improves Outcomes in Advanced Melanoma
June 06, 2021

Nivolumab monotherapy, or in combination with ipilimumab, continued to demonstrate durable improvements in overall survival compared with ipilimumab alone in patients with previously untreated advanced melanoma.